Last reviewed · How we verify
Intranasal Mupirocin and Topical Chlorhexidine
Intranasal Mupirocin and Topical Chlorhexidine is a Topical antibiotic combination Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization, Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage.
Intranasal mupirocin and topical chlorhexidine work together to eliminate and prevent nasal colonization of pathogenic bacteria, particularly Staphylococcus aureus.
Intranasal mupirocin and topical chlorhexidine work together to eliminate and prevent nasal colonization of pathogenic bacteria, particularly Staphylococcus aureus. Used for Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization, Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage.
At a glance
| Generic name | Intranasal Mupirocin and Topical Chlorhexidine |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Drug class | Topical antibiotic combination |
| Target | Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase, effectively killing susceptible bacteria in the nasal cavity. Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins. Together, this combination targets and eradicates nasal carriage of antibiotic-resistant pathogens, reducing the risk of subsequent infection.
Approved indications
- Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization
- Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage
Common side effects
- Nasal irritation or discomfort
- Local allergic reaction
- Headache
Key clinical trials
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Mupirocin-Iodophor ICU Decolonization Swap Out Trial (PHASE4)
- Topical Steroids & Bacterial Decolonization for Radiation Dermatitis (PHASE2)
- Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans (PHASE4)
- Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization (PHASE4)
- Active Bathing to Eliminate Infection (ABATE Infection) Trial (NA)
- Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) (NA)
- Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal Mupirocin and Topical Chlorhexidine CI brief — competitive landscape report
- Intranasal Mupirocin and Topical Chlorhexidine updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI
Frequently asked questions about Intranasal Mupirocin and Topical Chlorhexidine
What is Intranasal Mupirocin and Topical Chlorhexidine?
How does Intranasal Mupirocin and Topical Chlorhexidine work?
What is Intranasal Mupirocin and Topical Chlorhexidine used for?
Who makes Intranasal Mupirocin and Topical Chlorhexidine?
What drug class is Intranasal Mupirocin and Topical Chlorhexidine in?
What development phase is Intranasal Mupirocin and Topical Chlorhexidine in?
What are the side effects of Intranasal Mupirocin and Topical Chlorhexidine?
What does Intranasal Mupirocin and Topical Chlorhexidine target?
Related
- Drug class: All Topical antibiotic combination drugs
- Target: All drugs targeting Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
- Manufacturer: University of Maryland, Baltimore — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention of surgical site infections by reducing nasal Staphylococcus aureus colonization
- Indication: Drugs for Decolonization of methicillin-resistant Staphylococcus aureus (MRSA) nasal carriage
- Compare: Intranasal Mupirocin and Topical Chlorhexidine vs similar drugs
- Pricing: Intranasal Mupirocin and Topical Chlorhexidine cost, discount & access